<DOC>
	<DOCNO>NCT01325220</DOCNO>
	<brief_summary>There four study period : Screening ( 14 day length ) , Treatment Period ( 8 week ) , Withdrawal Period ( 22 day ) , Follow-up Period ( 31 day ) . Subjects randomize receive either STX209 ( 5 mg twice daily [ BID ] , 10 mg BID 10 mg three time daily [ TID ] ) placebo . Efficacy , safety tolerability assessment perform periodically</brief_summary>
	<brief_title>Efficacy Safety Study STX209 ( Arbaclofen ) Treatment Social Withdrawal Children With Fragile X Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<criteria>Molecular documentation full FMR1 mutation Current pharmacological treatment regimen stable least 4 week prior Screening . Subjects history seizure disorder must currently receive treatment antiepileptic must seizure free 6 month , must seizure free 3 year currently receive antiepileptic . If subject already receive stable nonpharmacologic educational , behavioral , and/or dietary intervention , participation program must continuous 2 month prior Screening Subjects condition , include alcohol drug abuse , might interfere conduct study , confound interpretation study result , endanger wellbeing . Subjects plan initiate change pharmacologic nonpharmacologic intervention course study . Subjects take another investigational drug within last 30 day . Subjects able take oral medication</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>